首页> 外文期刊>Journal of Neuropathology and Experimental Neurology >Differential Expression of CCN1/CYR61, CCN3/NOV, CCN4/WISP1, and CCN5/WISP2 in Neurofibromatosis Type 1 Tumorigenesis
【24h】

Differential Expression of CCN1/CYR61, CCN3/NOV, CCN4/WISP1, and CCN5/WISP2 in Neurofibromatosis Type 1 Tumorigenesis

机译:CCN1 / CYR61,CCN3 / NOV,CCN4 / WISP1和CCN5 / WISP2在神经纤维瘤病1型肿瘤发生中的差异表达

获取原文
获取原文并翻译 | 示例
           

摘要

The hallmark of neurofibromatosis type 1 is the development of dermal and plexiform neurofibromas. Neurofibromatosis type 1 patients with plexiform neurofibromas are at risk of developing malignant peripheral nerve sheath tumors. We applied a 22,000-oligonucleotide microarray transcriptomic approach to a series of plexiform neurofibromas in comparison with dermal neurofibromas, and results were confirmed with real-time quantitative reverse transcription-polymerase chain reaction. Thirteen genes were upregulated and 10 were downregulated in plexiform neurofibromas. The upregulated genes mainly encode molecules involved in cell adhesion, extracellular matrix, fibrogenesis, and angiogenesis. Several CCN gene family members were dysregulated in neurofibromatosis type 1 tumorigenesis; the angiogenic gene CCN1/CYR61 was specifically upregulated in the plexiform neurofibromas; CCN4/WISP1 was upregulated, and CCN3/NOV and CCN5/WISP2 were downregulated in paired comparisons of plexiform neurofibroma and malignant peripheral nerve sheath tumor from the same patients. CCN1 and CCN3 proteins were detected by immunohistochemistry in neurofibromatosis type 1-associated tumors. Upregulation of S100A8, S100A9, and CD36 was also observed and suggests a role of this pathway in inflammation-associated genesis of plexiform neurofibromas. In summary, a limited number of pathways are potentially involved in plexiform neurofibroma development. Some of the genes identified, particularly CCN1, might be useful diagnostic or prognostic markers or form the basis for novel therapeutic strategies.
机译:1型神经纤维瘤病的标志是皮肤和丛状神经纤维瘤的发展。患有丛状神经纤维瘤的1型神经纤维瘤病患者有发展为恶性周围神经鞘瘤的风险。与皮肤神经纤维瘤相比,我们对一系列丛状神经纤维瘤应用了22,000个寡核苷酸微阵列转录组学方法,并通过实时定量逆转录-聚合酶链反应证实了结果。在丛状神经纤维瘤中,十三种基因被上调,十种基因被下调。上调的基因主要编码涉及细胞粘附,细胞外基质,纤维生成和血管生成的分子。几个CCN基因家族成员在1型神经纤维瘤病的肿瘤发生中失调。血管生成基因CCN1 / CYR61在丛状神经纤维瘤中特异性上调。在同一患者的丛状神经纤维瘤和恶性周围神经鞘瘤的配对比较中,CCN4 / WISP1被上调,而CCN3 / NOV和CCN5 / WISP2被下调。通过免疫组织化学在神经纤维瘤病1型相关肿瘤中检测到CCN1和CCN3蛋白。还观察到S100A8,S100A9和CD36的上调,并表明该途径在丛发性神经纤维瘤的炎症相关起源中的作用。总之,有限数量的途径潜在地参与了丛状神经纤维瘤的发展。鉴定出的某些基因,特别是CCN1,可能是有用的诊断或预后标志物,或构成新治疗策略的基础。

著录项

  • 来源
  • 作者单位

    Eric Pasmant, PharmD, Nicolas Ortonne, MD, PhD, Laure Rittié, PhD, Ingrid Laurendeau, MSc, Pascale Lévy, PharmD, PhD, Vladimir Lazar, MD, PhD, Béatrice Parfait, PharmD, PhD, Karen Leroy, MD, PhD, Philippe Dessen, MD, PhD, Laurence Valeyrie-Allanore, MD, PhD, Bernard Perbal, PhD, Pierre Wolkenstein, MD, PhD, Michel Vidaud, PharmD, PhD, Dominique Vidaud, PharmD, PhD, and Ivan Bièche, PharmD, PhDFrom the UMR745 INSERIVI (EP, IL, PL, BP, MV, DV, IB), Université Paris Descartes, Faculté des Sciences Pharmaceutiques et Biologiques Paris, Service de Biochimie et de Génétique Moléculaire (EP, IL, BP, MV, DV, IB), Hôpital Beaujon, AP-HP, Clichy, and Département d'Anatomo-Cytopathologie AP-HP and Université Paris XII (NO), Hôpital Flenri-Mondor, Créteil, Fiance, Department of Dermatology (LR), University of Michigan Medical School, Ann Arbor, Michigan, and Functional Genomic Unit, Institut Gustave-Roussy (VL), Villejuif, Platform of Biological Resources, AP-HP and Université Paris XII (KL), Hôpital Henri-Mondor, Créteil, CNRS UMR 8125 Bioinformatics Unit, Institut Gustave-Roussy (PD), Villejuif, Département of Dermatologie. AP-HP and Université Paris XII (LV-A, PW), Hôpital Henri-Mondor. Créteil, Laboratoire d'Oncologie Virale et Moléculaire (BP), Université Paris 7-D. Diderot, Paris, and INSERM U735, Centre René Huguenin (IB), Saint-Cloud, France.Send correspondence and reprint requests to: Eric Pasmant, PharmD, UMR745 INSERM, Université Paris Descartes, Faculté des Sciences Pharmaceutiques et Biologiques, 4 avenue de l'Observatoire, 75006, Paris, France, E-mail: eric.pasmant@etu.univ-paris5.frThis work was supported by the Association Neurofibromatoses et Recklinghausen, Ligue Française Contre les Neurofibromatoses, INSERM Projet NF1GeneModif, and Ministère de l'Enseignement Supérieur et de la Recherche. Anti-CCN1 and anti-CCN3 antibody preparation was financed with an endowment granted to Pr. Perbal from the Ministere de la Recherche et de l'Education Nationale.Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.jneuropath.com). Online-only figures are available at http://www.jneuropath.com.,;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号